Modelling alternative treatment strategies for onchocerciasis: moxidectin for control and elimination

This projects involves projecting the potential epidemiological impact of using moxidectin—repurposed from veterinary to human medicine—to accelerate progress towards the elimination of onchocerciasis (river blindness) in Africa. The work will translate existing individual data from phase II and phase III clinical trials that show superiority of moxidectin over ivermectin—the current gold standard treatment for onchocerciasis—into population-level health benefits and revised timelines to elimination.